

Title (en)
Dihydrothienopyrimidines for the treatment of inflammatory diseases

Title (de)
Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen

Title (fr)
Dihydrothienopyrimidines pour le traitement de maladies inflammatoires

Publication
EP 1847543 A1 20071024 (DE)

Application
EP 06112779 A 20060419

Priority
EP 06112779 A 20060419

Abstract (en)

Thienopyrimidine derivatives (I) are new. Thienopyrimidine derivatives (I) of formula 1 are new. X : SO or SO₂; R¹ > H, 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 6-10C aryl, (6-10C)aryl(1-6C)alkyl or (5-10C)heteroaryl(1-6C)alkyl; R² > H; 1-10C alkyl, 2-6C alkenyl or 2-6C alkynyl optionally substituted with halo or Q¹; or 3-10C cycloalkyl optionally bridged with 1-3C alkyl and optionally substituted with Q²; 6-10C aryl optionally substituted with Q³; 3-10C heterocyclyl or 5-10C heteroaryl optionally substituted with halo, OH, oxo or Q⁴; NR¹ > R² > a 4-7C ring optionally substituted with OH, OR¹¹ >, 1-6C alkanol, oxo, halo, 1-6C alkyl, 6-10C aryl, COOR²¹ >, CONR²² > R²³ >, CH²NR²² > R²³ > or NR²² > R²³ >; Q¹ : OR²¹ >, COOR²¹ >, SR²¹ >, 6-10C aryl, 3-10C heterocyclyl, 5-10C heteroaryl, 3-10C (bi)cycloalkyl, CH²NR²² > R²³ > or NR²² > R²³ >, optionally substituted with OH, halo, OR²¹ >, oxo, 1-6C alkyl, 6-10C aryl, COOR²¹ >, CH²NR²² > R²³ > or NR²² > R²³ >; Q² : 1-6C alkanol, OR²¹ >, COOR²¹ >, 3-10C heterocyclyl, 6-10C aryl, 1-6C alkyl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 3-10C (bi)cycloalkyl and NR²² > R²³ >, optionally substituted with OH, halo, OR²¹ >, oxo, 1-6C alkyl, 6-10C aryl, CH²NR²² > R²³ >; Q³ : OR²¹ >, COOR²¹ >, NR²² > R²³ >, CH²NR²² > R²³ >, 3-10C cycloalkyl, 3-10C heterocyclyl, 1-6C alkyl, (6-10C)aryl(1-6C)alkyl, (3-10C)heterocyclyl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 6-10C aryl, SO²Me, SO²Et and SO²NR²² > R²³ >, optionally substituted with OH, halo, OR²¹ >, oxo, 1-6C alkyl, 6-10C aryl, NR²² > R²³ >; Q⁴ : OR²¹ >, COOR²¹ >, SR²¹ >, 6-10C aryl, 1-6C alkyl, 3-10C heterocyclyl, 5-10C heteroaryl, 3-10C cycloalkyl, 1-6C alkanol or NR²² > R²³ >, optionally substituted with OH, halo, OR²¹ >, oxo, 1-6C alkyl, 6-10C aryl or NR²² > R²³ >; R²¹ > 1-6C alkyl, 3-10C (bi)cycloalkyl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, (3-10C)heterocyclyl(1-6C)alkyl, (3-10C)cycloalkyl(1-6C)alkyl, 6-10C aryl, 5-10C heteroaryl or heterocyclyl, optionally substituted with OH, halo, 1-6C alkyl or 6-10C aryl; R²² >, R²³ > H, halo, 1-6C alkyl, 3-10C (bi)cycloalkyl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 6-10C aryl, 3-10C heterocyclyl, 5-10C heteroaryl, CONH², CONHMe, CONMe², 1-2C alkylsulfonyl, COR²¹ > or COOR²¹ >, optionally substituted with OH, halo, OR²¹ >, oxo, 1-6C alkyl, 6-10C aryl or NR²² > R²³ >; R³ > halo or CN; (3-10C)heterocyclyl(1-6C)alkyl optionally substituted with OH, halo, oxo, 1-6C alkyl or 6-10C aryl; 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 6-10C aryl; (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 3-10C heterocyclyl or 3-10C cycloalkyl, optionally substituted with OH, halo, oxo, 1-6C alkyl; CONR³¹ > R³² >; NR³³ > CONR³⁴ >; or SO²NR³⁵ > R³⁶ >; R³¹ >, R³² > H or 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 6-10C aryl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkynyl, (5-10C)heteroaryl(1-6C)alkenyl, 3-10C heterocyclyl, (3-10C)heterocyclyl(1-6C)alkyl or 5-10C heteroaryl, optionally substituted with OH, oxo, halo, 1-6C alkyl and 1-6C alkoxy; R³³ > H or 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 6-10C aryl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 3-10C heterocyclyl or 5-10C heteroaryl, optionally substituted with OH, OR²¹ >, oxo, NH², NR²² > R²³ >, halo, 1-6C alkyl or 6-10C aryl; R³⁴ > H or 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C alkanol, OR²¹ >, 2-7C alkanoyloxymethyl, NR²² > R²³ >, CH²NR²² > R²³ >, 6-10C aryl, (6-10C)aryl(1-6C)alkyl, (5-10C)heteroaryl(1-6C)alkyl, 3-10C heterocyclyl or 5-10C heteroaryl, optionally substituted with OH, OR²¹ >, oxo, NH², NR²² > R²³ >, halo, 1-6C alkyl or 6-10C aryl; R³⁵ >, R³⁶ > H, 1-6C alkyl or 6-10C aryl. Independent claims are also included for thienopyrimidine derivatives of formula 3-8. Y : H, Me or Et. [Image] ACTIVITY : Antiinflammatory; Antiarthritic; Dermatological; Ophthalmological; Cytostatic; Neuroprotective; Antiasthmatic; Antiulcer; Antidepressant; Antimanic; Tranquilizer; Neuroleptic; Nootropic; Antiparkinsonian; Cerebroprotective. No biological data given. MECHANISM OF ACTION : Phosphodiesterase PD4 inhibitor.

Abstract (de)

Die Erfindung betrifft neue Dihydrothienopyrimidine der Formel 1, sowie pharmakologisch verträgliche Salze, Diastereomere, Enantiomere, Racemate, Hydrate oder Solvate davon, die geeignet sind zur Behandlung von Atemwegs- oder gastrointestinalen Beschwerden oder Erkrankungen, entzündlichen Erkrankungen der Gelenke, der Haut oder der Augen, Erkrankungen des peripheren oder zentralen Nervensystems oder Krebserkrankungen, sowie pharmazeutische Zusammensetzungen die diese Verbindungen beinhalten.

IPC 8 full level

C07D 495/04 (2006.01); **A61K 31/519** (2006.01); **A61P 11/00** (2006.01)

CPC (source: EP KR US)

A61K 31/519 (2013.01 - KR US); **A61K 31/5377** (2013.01 - US); **A61K 45/06** (2013.01 - US); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 495/04** (2013.01 - EP KR US); **C07D 519/00** (2013.01 - EP US)

Citation (applicant)

- US 3318881 A 19670509 - GERHARD OHNACKER, et al
- BE 663693 A
- WO 03105853 A1 20031224 - CHEMOCENTRYX INC [US], et al
- WO 0230928 A1 20020418 - BOEHRINGER INGELHEIM PHARMA [DE], et al
- WO 03000265 A1 20030103 - BOEHRINGER INGELHEIM PHARMA [DE], et al
- J. MED. CHEM., vol. 33, 1990, pages 327
- BIOORG. MED. CHEM. LETT., vol. 743, 2002

Citation (search report)

[A] CHAKRABORTI, ASIT K. ET AL: "3D-QSAR Studies on thieno[3,2-d]pyrimidines as Phosphodiesterase IV Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 13(8), 1403-1408 CODEN: BMCLE8; ISSN: 0960-894X, 2003, XP002392463

Cited by

EP2380891A1; EP2610258A1; EA019480B1; WO2009050248A1; WO2009050236A1; WO2009053268A1; US8486948B2; US9090626B2; US8637519B2; US9115142B2; US8754073B2; US8604039B2; US8609670B2; US9150586B2; US9802954B2; US10745411B2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

EP 1847543 A1 20071024; AR 060516 A1 20080625; AU 2007239573 A1 20071025; BR PI0710459 A2 20110816; CA 2647243 A1 20071025; CN 101426505 A 20090506; CO 6140032 A2 20100319; EA 200802051 A1 20090428; EC SP088738 A 20081031; EP 2010185 A1 20090107; EP 2010185 B1 20120613; IL 194739 A0 20090803; JP 2010523467 A 20100715; JP 5214588 B2 20130619; KR 20090009885 A 20090123; MX 2008012915 A 20081015; NO 20083710 L 20081118; PE 20080319 A1 20080513; TW 200808811 A 20080216; US 2008096882 A1 20080424; US 2012108534 A1 20120503; US 2014005154 A1 20140102; US 8114878 B2 20120214; US 8604039 B2 20131210; US 8822474 B2 20140902; UY 30287 A1 20071130; WO 2007118793 A1 20071025; ZA 200807015 B 20100127

DOCDB simple family (application)

EP 06112779 A 20060419; AR P070101646 A 20070418; AU 2007239573 A 20070403; BR PI0710459 A 20070403; CA 2647243 A 20070403; CN 200780014008 A 20070403; CO 08111120 A 20081017; EA 200802051 A 20070403; EC SP088738 A 20080915; EP 07727726 A 20070403; EP 2007053255 W 20070403; IL 19473908 A 20081022; JP 2009505831 A 20070403; KR 20087028318 A 20081119; MX 2008012915 A 20070403; NO 20083710 A 20080828; PE 2007000470 A 20070417; TW 96113678 A 20070418; US 201213343391 A 20120104; US 201314019019 A 20130905; US 73670307 A 20070418; UY 30287 A 20070416; ZA 200807015 A 20080814